Literature DB >> 23959478

Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A.

Sining Shen, Han Yue, Yin Li, Jianjun Qin, Ke Li, Ying Liu, Jiaxiang Wang.   

Abstract

MicroRNAs (miRNAs) have been integrated into cancer development and progression, because they repress translation of target genes which can be tumor suppressors and oncogenes. A number of miRNAs have been found to be closely related to human non-small cell lung cancer (NSCLC). However, the roles of miR-136 in NSCLC are still largely unknown. Here, we show that miR-136 is significantly upregulated in human NSCLC primary tumors and cell lines compared to their nontumor counterparts. Suppression of miR-136 expression in NSCLC cell line A549 inhibited both anchorage-dependent and anchorage-independent proliferation. Further studies showed that suppression of miR-136 expression attenuated phosphorylation of extracellular-signal-regulated kinase 1/2 (Erk1/2). We found that serine/threonine protein phosphatase 2A 55 kDa regulatory subunit B α isoform (PPP2R2A, also known as B55α) was a direct target of miR-136, and suppression of miR-136 expression led to a robust increase in both mRNA and protein levels of PPP2R2A. We found that miR-136 promoted phosphorylation of Erk1/2 through inhibition of PPP2R2A expression, and forced overexpression of PPP2R2A abrogated promotion of Erk1/2 phosphorylation by miR-136. Moreover, forced overexpression of PPP2R2A abrogated the promoting effect of miR-136 on cell growth and led to a reduced growth rate of NSCLC cells. Our findings indicate that miR-136 promotes Erk1/2 phosphorylation through targeting PPP2R2A in NSCLC cells and suggest that it may serve as a therapeutic target in NSCLC therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23959478     DOI: 10.1007/s13277-013-1087-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  Overexpression of the protein phosphatase 2A regulatory subunit Bgamma promotes neuronal differentiation by activating the MAP kinase (MAPK) cascade.

Authors:  Stefan Strack
Journal:  J Biol Chem       Date:  2002-08-20       Impact factor: 5.157

2.  Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

Authors:  Yoko Karube; Hisaaki Tanaka; Hirotaka Osada; Shuta Tomida; Yoshio Tatematsu; Kiyoshi Yanagisawa; Yasushi Yatabe; Junichi Takamizawa; Shinichiro Miyoshi; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Sci       Date:  2005-02       Impact factor: 6.716

3.  Human microRNA clusters: genomic organization and expression profile in leukemia cell lines.

Authors:  Jia Yu; Fang Wang; Gui-Hua Yang; Fan-Long Wang; Yan-Ni Ma; Zhan-Wen Du; Jun-Wu Zhang
Journal:  Biochem Biophys Res Commun       Date:  2006-08-11       Impact factor: 3.575

4.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 6.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

7.  B55alpha PP2A holoenzymes modulate the phosphorylation status of the retinoblastoma-related protein p107 and its activation.

Authors:  Girish Jayadeva; Alison Kurimchak; Judit Garriga; Elena Sotillo; Anthony J Davis; Dale S Haines; Marc Mumby; Xavier Graña
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

8.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

Review 10.  MicroRNAs regulation modulated self-renewal and lineage differentiation of stem cells.

Authors:  Shih-Ping Liu; Ru-Huei Fu; Hsiu-Hui Yu; Kuo-Wei Li; Chang-Hai Tsai; Woei-Cherng Shyu; Shinn-Zong Lin
Journal:  Cell Transplant       Date:  2009-04-29       Impact factor: 4.064

View more
  35 in total

1.  miR-660 promotes liver cancer cell proliferation by targeting PPP2R2A.

Authors:  Yaozhen Pan; Lei Zhan; Ling Chen; Liwen Chen; Chengyi Sun
Journal:  Exp Ther Med       Date:  2021-04-25       Impact factor: 2.447

2.  MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression.

Authors:  Jianting Long; Caiwen Ou; Haoming Xia; Yifan Zhu; Dayue Liu
Journal:  Tumour Biol       Date:  2015-06-06

3.  Downregulation of miR-136 promotes the progression of osteosarcoma and is associated with the prognosis of patients with osteosarcoma.

Authors:  Yanchen Chu; Xiaoli Hu; Guangfeng Wang; Zhijie Wang; Yanjin Wang
Journal:  Oncol Lett       Date:  2019-04-01       Impact factor: 2.967

4.  MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells.

Authors:  Wanghao Chen; Yong Yang; Bo Chen; Peisong Lu; Liping Zhan; Qiang Yu; Kan Cao; Qiaoyu Li
Journal:  J Neurooncol       Date:  2014-08-20       Impact factor: 4.130

5.  Long noncoding RNA CRNDE activates Wnt/β-catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer.

Authors:  Jinliang Huan; Li Xing; Qianhuang Lin; Hu Xui; Xianju Qin
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

Review 6.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

7.  Microrna-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway.

Authors:  Xuyan Chen; Zhiming Huang; Renpin Chen
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

8.  Regulation of polo-like kinase 1 by DNA damage and PP2A/B55α.

Authors:  Ling Wang; Qingyuan Guo; Laura A Fisher; Dongxu Liu; Aimin Peng
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Tumor suppressor microRNA-136-5p regulates the cellular function of renal cell carcinoma.

Authors:  Peijie Chen; Liwen Zhao; Xiang Pan; Lu Jin; Canbin Lin; Weijie Xu; Jinling Xu; Xin Guan; Xueling Wu; Yong Wang; Shangqi Yang; Tao Wang; Yongqing Lai
Journal:  Oncol Lett       Date:  2018-02-16       Impact factor: 2.967

10.  Induction of cancer-related microRNA expression profiling using excretory-secretory products of Clonorchis sinensis.

Authors:  Jhang Ho Pak; In Ki Kim; Seon Min Kim; Sejung Maeng; Kyoung Ju Song; Byoung-Kuk Na; Tong-Soo Kim
Journal:  Parasitol Res       Date:  2014-09-14       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.